Opinion Statement
Cardiac resynchronization therapy (CRT) is an important therapy in heart failure but 30 %‒40 % of patients may not respond. Improving this rate is an important goal and requires attention to candidate selection, intraoperative procedure, and postoperative follow-up. Factors to be considered are QRS morphology, duration, and left ventricular lead position with attention to paced effects on QRS. Postprocedure follow-up is critical to correct interfering conditions (eg, anodal capture, loss of 100 % biventricular pacing because of premature ventricular complexes (PVCs) or atrial fibrillation (AF). Echocardiographic improvement following CRT, which may take up to 18 months, is a potent predictor of long-term outcomes. Correcting the status of nonresponders, when possible, is important. Remote monitoring, in conjunction with CRT optimization clinics, may facilitate multidisciplinary follow-up and enable early intervention to improve outcome.
Similar content being viewed by others
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
Cazeau S, Leclercq C, Lavergne T, Walker S, Varma C, Linde C, et al. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med. 2001;344(12):873–80.
Abraham WT, Fisher WG, Smith AL, Delurgio DB, Leon AR, Loh E, et al. Cardiac-resynchronization in chronic heart failure. N Engl J Med. 2002;346:1845–53.
Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, et al. Cardiac resynchronization therapy without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350:2140–50.
Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352:1539–49. Landmark trial showing that CRT imparts survival benefit in heart failure patients.
Linde C, Abraham WT, Gold MR, et al. Randomized trial of resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. J Am Coll Cardiol. 2008;52:1834–43.
Daubert C, Gold MR, Abraham WT, et al. Prevention of disease progression by cardiac resynchronization therapy in patients with asymptomatic or mildly symptomatic left ventricular dysfunction. J Am Coll Cardiol. 2009;54:1837–46.
Moss AJ, Hall WJ, Cannom DS, et al. Cardiac-resynchronization therapy for the prevention of heart failure events. N Engl J Med. 2009;361:1329–38.
Tang AS, Wells GA, Talajic M, Arnold MO, Sheldon R, Connolly S. Resynchronization-defibrillation for ambulatory heart failure trial investigators. N Engl J Med. 2010;363:2385–95.
Rickard J, Brennan DM, Martin DO, Hsich E, Tang WH, Lindsay BD, et al. The impact of left ventricular size on response to cardiac resynchronization therapy. Am Heart J. 2011;162:646–53.
Birnie DH, Tang AS. The problem of nonresponse to cardiac resynchronization therapy. Curr Opin Cardiol. 2006;219:20–6.
ACC/AHA/HRS. Guidelines for device-based therapy of cardiac rhythm abnormalities. report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 guideline update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. J Am Coll Cardiol. 2008;51(21):2085–105.
Rickard J, Kumbhani DJ, Gorodeski EZ, Baranowski B, Wazni O, Martin DO, et al. Cardiac resynchronization therapy in non-left bundle branch block morphologies. Pacing Clin Electrophysiol. 2010;33:590–5.
Adelstein E, Saba S. Usefulness of baseline electrocardiographic QRS complex pattern to predict response to cardiac resynchronization. Am J Cardiol 2008; 238‒42.
Tompkins C, Kutyifa V, McNitt S, Polonsky B, Klein HU, Moss AJ, Zareba W. Effect on cardiac function of cardiac resynchronization therapy in patients with right bundle branch block (from the Multicenter Automatic Defibrillator Implantation trial with Cardiac Resynchronization Therapy [MADIT-CRT] Trial) 2013;112:525‒9.
Rickard J, Bassiouny M, Cronin EM, Martin DO, Varma N, Niebauer MJ, et al. Predictors of response to cardiac resynchronization therapy in patients with a non-left bundle branch block morphology. Am J Cardiol. 2011;108:1576–80.
Epstein AE, DiMarco JP, Ellenbogen KA, Estes III NA, Freedman RA, Gettes LS, et al. American College of Cardiology Foundation; American Heart Association Task Force on practice guidelines; Heart Rhythm Society. 2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2013;61(3):e6–e75.
Cuoco FA, Gold MR. Optimization of cardiac resynchronization therapy: importance of programmed parameters. J Cardiovasc Electrophysiol. 2012;23:110–8.
Worley SJ. CRT delivery systems based on guide support for LV lead placement. Heart Rhythm. 2009;6:1383–7.
Blendea D, Singh JP. Lead positioning strategies to enhance response to cardiac resynchronization therapy. Heart Fail Rev. 2011;16:291–303.
Heist EK, Fan D, Mela T, et al. Radiographic left ventricular-right ventricular interlead distance predicts the acute hemodynamic response to cardiac resynchronization therapy. Am J Cardiol. 2005;96:685–90.
Singh JP, Fan D, Heist EK, et al. Left ventricular lead electrical delay predicts response to cardiac resynchronization therapy. Heart Rhythm. 2006;3:1285–92.
Becker M, Franke A, Breithardt OA, et al. Impact of left ventricular lead position on the efficacy of cardiac resynchronization therapy: a two-dimensional strain echocardiography study. Heart. 2007;93:1197–203.
Singh JP, Klein HU, Huang DT, Reek S, Kuniss M, Quesada A, et al. Left ventricular lead position and clinical outcome in the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy (MADIT-CRT) trial. Circulation. 2011;22:1159–66. Nonapical LV lead position were associated with negative outcomes to CRT.
Wilkoff BL, Cook JR, Epstein AE, Greene HL, Hallstrom AP, Hsia H, et al. Dual Chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: the Dual Chamber and VVI Implantable Defibrillator (DAVID) trial. JAMA. 2002;288:3115–23.
Wilton SB, Shibata MA, Sondergaard R, Cowan K, Semeniuk L, Exner DV. Relationship between left ventricular lead position using a simple radiographic classification scheme and long term outcome with resynchronization therapy. J Interv Card Electrophysiol. 2008;23:219–27.
Rademakers LM, van Kerckhoven R, van Deursen CJ, et al. Myocardial infarction does not preclude electrical and hemodynamic benefits of cardiac resynchronization therapy in dyssynchronous canine hearts. Circ Arrythm Electrophysiol. 2010;3:361–58.
Bleeker GB, Kaandorp TA, Lamb HJ, Boersma E, Steendijk P, de Roos A, et al. Effect of posterolateral scar tissue on clinical and echocardiographic improvement after cardiac resynchronization therapy. Circulation. 2006;113:969–76.
White JA, Yee R, Yuan X, Krahn A, Skanes A, Parker M, et al. Delayed enhancement magnetic resonance imaging predicts response to cardiac resynchronization therapy in patients with intraventricular dyssynchrony. J Am Coll Cardiol. 2006;48:1953–60.
Marsan NA, Westenberg JJ, Ypenburg C, van Bommel RJ, Roes S, Delgado V, et al. Magnetic resonance imaging and response to cardiac resynchronization therapy: relative merits of left ventricular dyssynchrony and scar tissue. Eur Heart J. 2009;30:2360–7.
Varma N. Cardiac resynchronization therapy and the electrical substrate in heart failure: what does the QRS conceal ? Heart Rhythm. 2009;6:1059–62.
Varma N. Variegated left ventricular electrical activation in response to a novel quadripolar electrode-visualization by noninvasive electrocardiographic imaging. J Electrocard. 2013; 47: 66–74
van Rees JB, de Bie MK, Thijssen J, Borleffs CJ, Schalij MJ, van Erven L. Implantation-related complications of implantable cardioverter-defibrillators and cardiac resynchronization therapy devices. J Am Coll Cardiol. 2011;58:995–1000.
Tomassoni G, Baker J, Corbisiero R, Love C, Martin D, Niazi I, et al. Postoperative performance of the Quartet® left ventricular heart lead. J Cardiovasc Electrophysiol. 2013;24:449–56.
Reynolds MR, Cohen DJ, Kugelmass AD, et al. The frequency and incremental cost of major complications among Medicare beneficiaries receiving Implantable Cardioverter-Defibrillators. J Am Coll Cardiol. 2006;47:2493–7.
Poole JE, Gleva MJ, Mela T, Chung MK, Uslan DZ, Borge R, et al. Complication rates associated with pacemaker or Implantable Cardioverter-Defibrillator generator replacements and upgrade procedures: results from the REPLACE registry. Circulation. 2010;122:1553–61.
Birnie DH, Healey JS, Wells GA, Verma A, Tang AS, Krahn AD, et al. Pacemaker or defibrillator surgery without interruption of anticoagulation. N Engl J Med. 2013;368:208–93.
Rowley CP, Bernard ML, Brabham WW, Netzler PC, Sidney DS, Cuoco F, et al. Safety of continuous anticoagulation with dabigatran during implantation of cardiac rhythm devices. Am J Cardiol. 2013;111:1165–8.
Rickard J, Jackson G, Spragg DD, Cronin EM, Baranowski B, Tang WH, et al. QRS prolongation induced by cardiac resynchronization therapy correlates with deterioration in left ventricular function. Heart Rhythm. 2012;9(10):1674–8.
Rickard J, Cheng A, Spragg D, Cantillon D, Chung MK, Wilson Tang W, et al. QRS narrowing is associated with reverse remodeling in patients with chronic right ventricular pacing upgraded to cardiac resynchronization therapy. Heart Rhythm. 2013;10:55–60. 37 and 38 describe the value of CRT paced ECGs in predicting outcome.
Hayes DL, Boehmer JP, Day JD, Gilliam III FR, Heidenreich PA, Seth M, et al. Cardiac resynchronization therapy and the relationship of percent biventricular pacing to symptoms and survival. Heart Rhythm. 2011;8:1469–75.
Ellenbogen KA, Gold MR, Meyer TE, Fernndez Lozano I, Mittal S, Waggoner AD, et al. Primary results from the SmartDelay determined AV optimization: a comparison to other AV delay methods used in cardiac resynchronization therapy (SMART-AV) trial: a randomized trial comparing empirical, echocardiography-guided, and algorithmic atrioventricular delay programming in cardiac resynchronization therapy. Circulation. 2010;122:2660–8.
Boriani G, Müller CP, Seidl KH, Grove R, Vogt J, Danschel W, et al. Randomized comparison of simultaneous biventricular stimulation versus optimized interventricular delay in cardiac resynchronization therapy. The Resynchronization for the HemodYnamic Treatment for Heart Failure Management II Implantable Cardioverter Defibrillator (RHYTHM II ICD) study. Am Heart J. 2006;15:1050–8.
Rao RK, Kumar UN, Schafer J, Viloria E, De LD, Foster E. Reduced volumes and improved systolic function with cardiac resynchronization therapy: a randomized controlled trial comparing simultaneous biventricular pacing, sequential biventricular pacing, and left ventricular pacing. Circulation. 2007;115:2136–44.
Mullens W, Grimm RA, Verga T, Dresing T, Starling RC, Wilkoff BL, et al. Insights from a cardiac resynchronization optimization clinic as part of a heart failure disease management program. J Am Coll Cardiol. 2009;53:765–73. This outlines the positive effect of a multidisciplinary clinic for follow-up of CRT patients.
Weiss, Raul, et al. V-V optimization in cardiac resynchronization therapy nonresponders: Response-HF trial results. Abstract AB12-5, HRS 2010, Denver, Colorado.
Ritter P, Padeletti L, Gillio-Meina L, Gaggini G. Determination of the optimal atrioventricular delay in DDD pacing. comparison between echo and peak endocardial acceleration measurements. Europace. 1999;2:126–30.
Nayer V, Khan FZ, Pugh PJ. Optimizing atrioventricular and interventricular intervals following cardiac resynchronization therapy. Expert Rev Cardiovasc Ther. 2011;9:185–97.
Colocousis JS, Huntsman LL, Curreri PW. Estimation of stroke volume changes by ultrasonic Doppler. Circulation. 1977;56:914–7.
Sogaard P, Egeblad H, Pedersen AK, Kim WY, Kristensen BO, Hansen PS, et al. Systemic versus simultaneous biventricular resynchronization for severe heart failure: evaluation by tissue Doppler imaging. Circulation. 2002;106:2078–84.
Ranjan R, Chiamvimon N, Thakor N, Tomaselli G, Marban E. Mechanism of anode stimulation in the heart. Biophys J. 1998;74:1850–63.
Dendy KF, Poweel BD, Cha YM, Espinosa RE, Friedman PA, Rea RF, et al. Anodal stimulation: an under-recognized cause of nonresponders to cardiac resynchronization therapy. Indian Pacing Electrophysiol. 2011;11:64–72.
Tamborero D, Mont L, Alanis R, Berruezo A, Tolosana JM, Sitges M, et al. Anodal capture in cardiac resynchronization therapy implications for device programming. PACE. 2006;29:940–5.
Ghio S, Freemantle N, Scelsi L, Serio A, Magrini G, Pasotti M, et al. Long-term left ventricular reverse remodelling with cardiac resynchronization therapy: results from the CARE-HF trial. Eur J Heart Fail. 2009;11:480–8.
Solomon SD, Foster E, Bourgoun M, Shah A, Viloria E, Brown MW, et al. Effect of cardiac resynchronization therapy on reverse remodeling and relation to outcome: Multicenter Automatic Defibrillator Implantation Trial: cardiac resynchronization therapy. Circulation. 2010;122:985–92. Outlines the relation between remodeling and outcome in CRT treated patients.
Rickard J, Kumbhani DJ, Popovic Z, Verhaert D, Manne M, Sraow D, et al. Characterization of super-response to cardiac resynchronization therapy. Heart Rhythm. 2010;7:885–9.
Hsu JC, Solomon SD, Bourgoun M, McNitt S, Goldenberg I, Klein H, et al. Predictors of super-response to cardiac resynchronization therapy and associated improvement in clinical outcome: the MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy) study. J Am Coll Cardiol. 2012;59:2366–73.
Manne M, Rickard J, Varma N, Chung MK, Tchou P. Normalization of left ventricular ejection fraction after cardiac resynchronization therapy also normalizes survival. Pacing Clin Electrophysiol. 2013;8:970–7.
Ruschitzka F. The challenge of non-responders to cardiac resynchronization therapy: lessons learned from oncology. Heart Rhythm. 2012;9(8 Suppl):S14–7.
Rickard J, Cheng A, Spragg D, Bansal S, Niebauer M, Baranowski B, Cantillon DJ, Tchou PJ, Grimm RA, Wilson Tang WH, Wilkoff BL, Varma N.Durability of the survival effect of cardiac resynchronization therapy by level of left ventricular functional improvement: Fate of nonresponders. Heart Rhythm. 2013. doi:10.1016/j.hrthm.2013.11.025.
Mullens W, Tang WH. Optimizing cardiac resynchronization therapy in advanced heart failure. Congest Heart Fail. 2011;17:147–51.
Altman RK, Parks KA, Schlett CL, Orencole M, Park MY, Truong QA, et al. Multidisciplinary care of patients receiving cardiac resynchronization therapy is associated with improved clinical outcomes. Eur Heart J. 2012;17:2181–8.
Varma N, Epstein AE, Irimpen A, Schweikert R, Love C. Efficacy and safety of automatic remote monitoring for Implantable Cardioverter-Defibrillator follow-up: the LUMOS-T safely reduces routine office device follow-up (TRUST) trial. Circulation. 2010;122:325–32. Landmark trial showing how automatic remote monitoring performs continuous monitoring of a large volume of heart failure patients yet reduces clinic workload while enabling early detection of salient problems.
Crossley GH, Boyle A, Vitense H, Chang Y, Mead RH. The CONNECT (clinical evaluation of remote notification to reduce time to clinical decision) trial: the value of wireless remote monitoring with automatic clinician alerts. J Am Coll Cardiol. 2011;57:1181–9.
Varma N, Wilkoff B. Device features for managing patients with heart failure. Heart Fail Clin. 2011;7:215–25. viii.
Saxon LA, Hayes DL, Gilliam FR, Heidenreich PA, Day J, Seth M, et al. Long-term outcome after ICD and CRT implantation and influence of remote device follow-up: the ALTITUDE survival study. Circulation. 2010;122:2359–67. Patients assigned to automatic remote monitoring during follow-up derived survival benefit.
Brignole M, Auricchio A, Baron-Esquivias G, Bordachar P, Boriani G, Breithardt OA, et al. ESC guidelines on cardiac pacing and cardiac resynchronization therapy: the task force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). developed in collaboration with the European Heart Rhythm Association (EHRA). Europace. 2013;15:1070–118.
Hindricks G, et al. In TIME Trial, Late Breaking Clinical Trial European Society of Cardiology Meeting Amsterdam, The Netherlands 2013.
Compliance with Ethics Guidelines
Conflict of Interest
Dr. John Rickard received honoraria from St. Jude Medical and travel/accommodations expenses covered or reimbursed by Medtronic Inc.
Dr. Niraj Varma received honoraria from Medtronic, St. Jude Medical, Boston Scientific, Sorin and Biotronik. Dr. Varma received payment for the development of educational presentations including service on speakers’ bureaus from Medtronic, Boston Scientific, St. Jude Medical and Biotronik. Dr. Varma received travel/accommodations expenses covered or reimbursed by St. Jude Medical, Biotronik, Medtronic, Sorin, and Boston Scientific.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Author information
Authors and Affiliations
Corresponding author
Additional information
This article is part of the Topical Collection on Heart Failure
Rights and permissions
About this article
Cite this article
Rickard, J., Varma, N. Periprocedural Management of Cardiac Resynchronization Therapy. Curr Treat Options Cardio Med 16, 298 (2014). https://doi.org/10.1007/s11936-014-0298-1
Published:
DOI: https://doi.org/10.1007/s11936-014-0298-1